Quote:

---

Ohm20, how does this compare to Leronlimab? Any thoughts?

---

Quote:

---

Gilead Sciences, Inc. today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC).
https://www.gilead.com/news/news-details/2025...ast-cancer

---

It would be impossible to make a true comparison because this trial is in first line treatment patients whose disease severity would be far less than in Cytodyn's patients. No overall survival data has been released for this Trodelvy study yet.

This study involved patients who already were positive for PD-L1 so they would be hot tumors. I have mentioned that leronlimab would enhance Trodelvy's tumor killing abilities. A combination of leronlimab, Trodelvy and a PD-L1 inhibitor would take care of tumors whether hot or cold.